AINOS INC

AIMDNASDAQ

🏆 #4263 by market capUS Equity

$1.47▼ $0.01 (−0.96%)

Live

1h—

24h▼ 1.0%

7d▲ 2.5%

14d▲ 7.0%

30d▼ 23.7%

1y▼ 55.3%

🏦Market Cap

$13M

Small Cap

📈Revenue Growth (YoY)

-87.7%

Declining

📊Gross Margin

78.8%

High

💵FCF Margin

1102.9%

Strong

⚖️P/S Ratio

776.4x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $1.44 – $1.48
52-Week Range: $1.26 – $4.44
Volume: $2.52B
Avg Volume: $2.74B
Shares Outstanding: 8.5M
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $124,157
Last Q Revenue: $152
P/E Ratio: —
P/S Ratio: 776.4x
EPS (TTM): $-2.53
Dividend Yield: —

Why Investors Own AIMD

✓High-growth profile — revenue up +43.8% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$124,157▲ +47.8% YoY

Gross Margin (TTM)

62.3%▲ +2.4% YoY

Operating Income (TTM)

$30,046▲ +47.8% YoY

Free Cash Flow (TTM)

$19,989▲ +47.8% YoY

About AINOS INC

Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.

🦦